“ASSESING THE RISK OF GERIATIC DISORDERS”
Being able to discover an accurate, timely diagnosis of current nonreversible declines in mental functionality is vital to building a future treatment plan. These diseases carry a significant burden on the client, the medical team, family, and friends. MicroGen Health is aware that every day available to implement proactive interventions could translate into weeks, months, or even years of beneficial life quality for the client.
In that spirit, our experts leverage our current panel to determine whether a client has inherited genetic mutations likely to result in geriatric or late-onset disorders such as Alzheimer’s, dementia, and Parkinson’s disease. Although each of these diagnoses tends to occur later in life, early onset is expected in the presence of inherited mutations.
Alzheimer’s-dementia-Parkinson’s genomics panel covers 34 genes
The earlier clients can be tested, the better. If a client is concerned about the possibility of a future diagnosis, they should reach out to their primary care provider for guidance. That provider will most likely review certain personal history and background medical information to determine if testing would be appropriate. Some of the reasons for ordering this test include:
Primary physicians should first conduct a pre-test genetic counseling session with their patients before referring them for testing. This is so all the appropriate questions are answered about the potential benefits and limitations of the test. There will then be a trained laboratory technician that will collect a whole blood sample or buccal swab of the client into a specific testing container. That sample will then be sent to our labs in a safe, temperature-controlled setting.
Genomic DNA will be carefully extracted from the collected sample by our expert technicians using the latest technology. Our lab will then assess the quality and quantity of the sample for genetic markers using generation sequencing. Our Bioinformatics tools will be implemented to understand the nature of any possible variants according to the guidelines set out by the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP).
The presence of pathogenic or likely pathogenic variants is indicated as a “positive” result. A positive result in a person affected may suggest an inherited mutation. A positive result in an asymptomatic individual suggests the possibility of potential high-risk, which could mean the need for either nutritional, therapeutic, or lifestyle interventions to reduce the risk of future diagnosis.
The presence of benign or likely benign variants is indicated as a “negative” result. This will inform the client’s physician on possible next steps, including evaluating other non-genetic causes for the specified phenotype. Post-test genetic counseling is suggested to help decide whether other members of the client’s family need to undergo this same genetic testing.
At MicroGen, we strive to provide only evidence-backed test results using experienced technicians and experts with the latest technology. We protect our client’s privacy according to industry standards and seek to have a professional customer interaction each and every time. If you would like to begin your test or have any other questions, please reach out to our team using our contact page. Thank you for considering MicroGen Health for your health care diagnostics.
|GRN||Neuronal ceroid lipofuscinosis 11||AD|
|POLG||Mitochondrial DNA depletion syndrome 4A||AD|
|C9orf72||Dementia, amyotrophic lateral sclerosis||AD|
|DNMT1||Hereditary sensory neuropathy Type Ie||AD|
|NOTCH3||Lateral Meningocele syndrome||AD|
AD: autosomal dominant; AR: autosomal recessive
1021 calendar days (14 days on average)
81161, 81405, 81406, 81407, 81439
NOTE: The CPT codes listed on the website are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients. Clients who bill for services should make the final decision on which codes to use.
99.0% of targeted genomic regions at 20X coverage or higher
Beckmann, B.M., Pfeufer, A., & Kääb, S. Inherited cardiac arrhythmias: diagnosis, treatment, and prevention. Dtsch Arztebl Int. 2011 Sep;108(37):623-33 (2011) Kimura, A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet. Jan;61(1):41-50 (2016)